- Home
- ENTA vs AZI Comparison
ENTA vs AZI Comparison
Compare ENTA & AZI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENTA | AZI |
|---|---|---|
| Founded | 1995 | 2010 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.5M | 1.2M |
| IPO Year | 2013 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ENTA | AZI |
|---|---|---|
| Price | $14.71 | $1.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $20.40 | N/A |
| AVG Volume (30 Days) | 288.3K | ★ 795.3K |
| Earning Date | 11-17-2025 | 01-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $65,324,000.00 | ★ $156,466,000.00 |
| Revenue This Year | $0.99 | N/A |
| Revenue Next Year | $0.19 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 32.90 |
| 52 Week Low | $4.09 | $1.62 |
| 52 Week High | $15.34 | $69.00 |
Technical Indicators
Market Signals| Indicator | ENTA | AZI |
|---|---|---|
| Relative Strength Index (RSI) | 67.09 | 96.66 |
| Support Level | $13.75 | $0.03 |
| Resistance Level | $14.79 | $0.06 |
| Average True Range (ATR) | 0.74 | 0.05 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 90.89 | 73.30 |
Price Performance
Historical ComparisonAbout ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
About AZI Autozi Internet Technology (Global) Ltd. Class A Ordinary Shares
Autozi Internet Technology (Global) Ltd provides high-quality, affordable, and professional one-stop automotive products and services through online and offline channels in China. Leveraging its online supply chain cloud platform, SaaS platforms, and the network of MBS stores, It has established an ecosystem of lifecycle automotive services by connecting automotive manufacturers, auto parts manufacturers, and insurance companies with MBS stores and various automotive owners. Its business segments include new car sales, auto parts and auto accessories sales, and automotive insurance-related services. The majority of revenue is from the new car sales segment, and auto parts & auto accessories sales.